Surgical ventricular restoration and other surgical approaches to heart failure.
Historically, few patients with ischemic congestive heart failure (CHF) have been considered for cardiac surgical intervention unless there was an obvious need for coronary revascularization or valve repair. New surgical procedures and non-mechanical assist devices are being used and tested in patients with end-stage CHF. We report on The Ohio State University Medical Center's early involvement in the international and multi-institutional Surgical Treatment for Ischemic Heart Failure (STICH) trial, which is evaluating the value of coronary artery bypass in patients with ischemic CHF as compared to medical therapies alone, and whether surgical ventricular restoration (SVR) offers additional benefit to patients with dilated hearts undergoing revascularization. Beyond standard coronary revascularization and SVR, new surgically deployed devices that attempt to augment ventricular performance by direct restraint of left ventricular dilatation or by reducing ventricular wall stress through altering ventricular shape are reviewed. The growing clinical and experimental experience with cellular cardiomyoplasty (in particular, autologous skeletal myoblast and adult-derived stem transplantation) also is reviewed. This review is intended to express the institutional insights of the authors, who have been involved in clinical trials and basic science research in each of these areas.
McConnell
Patrick I
PI
Division of Cardiothoracic Surgery, N847 Doan Hall, 410 W. 10th Avenue, Columbus, OH 43210, USA.
Michler
Robert E
RE
D000818:Animals; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D006333:Heart Failure / Q000601:surgery*; D006352:Heart Ventricles / Q000601:surgery*; D006353:Heart-Assist Devices; D006801:Humans; D032386:Myoblasts, Cardiac / Q000637:transplantation; D032448:Myoblasts, Skeletal / Q000637:transplantation; D033581:Stem Cell Transplantation